Norfolk, VA – March 28, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company...
Read MoreNorfolk, VA – February 21, 2024 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company...
Read MoreNew appointments bring deep research and development expertise and technology innovation to support continued advancement of ReAlta’s EPICC Technology Platform...
Read MoreNew appointments bring broad business management and commercial experience to support continued advancement of ReAlta’s multiple clinical programs Norfolk, VA...
Read MoreThird clinical indication under evaluation for RLS-0071, demonstrating the broad potential of ReAlta’s lead dual-action complement and innate inflammatory inhibitor...
Read MoreNorfolk, VA, October 12, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company focused on harnessing the...
Read MoreReAlta Life Sciences Receives FDA Clearance for Phase 2 Trial of RLS-0071 in Hospitalized Patients with Steroid-Refractory Acute Graft-Versus-Host Disease...
Read MoreNorfolk, VA, September 5, 2023 – ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company addressing life-threatening rare diseases...
Read MoreNORFOLK, Va., August 1, 2023 — ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening...
Read More